About this podcast
Tune in to BioCentury’s in-depth conversations with global leaders who are advancing the future of medicine.
Join our Senior Editors in face-to-face discussions with scientific KOLs, top executives, VCs, and key policymakers, dissecting the most urgent public health issues.
The BioCentury Show is THE only place where BioCentury’s experts join top innovators and global influencers to show how science is being turned into medicine.
Don't miss this event, every two weeks, now available as a video webcast or audio podcast.
Episodes
The newest 20 of 75 episodes
- Ep. 123 - Gilde’s Joep Muijrers on why patients belong in the investment process · 34 min · Season 5 Episode 123On this edition of The BioCentury Show, Gilde's Joep Muijrers joins BioCentury’s Stephen Hansen to discuss how the firm’s Impact Council of former regulators, payers, HTA…
- Ep. 122 - Tigermed's Britney Winterberger's take on running trials in the U.S. and China · 30 min · Season 5 Episode 122Tigermed, the largest clinical CRO in China, has expanded into more than 50 countries and is growing its North American operations, offering full-service support from preclinical…
- Ep. 121 - Arrowhead’s Chris Anzalone on the future of RNAi · 37 min · Season 5 Episode 121Arrowhead Pharmaceuticals can now deliver siRNA to seven cell types, and new data showing subcutaneous delivery to the brain could push RNAi therapies well beyond the liver. On…
- Ep. 120 - Canaan’s Julie Grant on building biotechs in white spaces · 39 min · Season 5 Episode 120Untapped multibillion-dollar markets are hiding in plain sight where patients endure mediocre generic standards of care, according to Canaan General Partner Julie Grant…
- Ep. 119 - Blackstone's Galakatos on funding biotech's hardest mile · 35 min · Season 5 Episode 119On this edition of The BioCentury Show, Nick Galakatos, Global Head of Life Sciences at Blackstone, joins Editor in Chief Simone Fishburn to discuss the path from Clarus to…
- Ep. 118 - Regeneron's Gonçalo Abecasis on turning genetic data into drug targets · 32 min · Season 5 Episode 118On This Edition of The BioCentury Show, Gonçalo Abecasis, SVP and Chief Genomics and Data Sciences Officer at the Regeneron Genetics Center, joins BioCentury’s Tierney Baum to…
- Ep. 117 - C-Path's Klaus Romero on moving genetic medicines beyond one patient · 30 min · Season 5 Episode 117The Critical Path Institute’s One to Millions Initiative is using individualized rare disease therapies as the starting point for a development framework that could eventually…
- Ep. 116 - Ovid's Jeremy Levin on biotech in the balance · 33 min · Season 5 Episode 116Throughout his career, which has included serving as president and CEO of Teva, chair of BIO, and a leader or senior executive of large and small biopharma companies, Jeremy…
- Ep. 115 - Initiate's Owens on what it takes to be AI-native · 40 min · Season 5 Episode 115As AI becomes increasingly commoditized, Initiate Ventures' Jessica Owens argues healthcare and life sciences companies need to use it to solve historically intractable problems…
- Ep. 114 - Roivant’s Matt Gline on commercial launches and the future of the vant model · 42 min · Season 5 Episode 114Roivant CEO Matt Gline calls the company’s move beyond spinning out subsidiary “vants” to concentrating on late-stage programs and commercial launches less a pivot than an…
- Ep. 113 - Frank Jiang on Hengrui’s rise and China’s new era of biopharma dealmaking · 35 min · Season 5 Episode 113Launched in the 1970s as a generics company, Hengrui has become China’s leading innovator in R&D and dealmaking, with more than 100 NMEs in the pipeline and broad alliances with…
- Ep. 112 - Chris Arendt on rebuilding Takeda for AI · 40 min · Season 5 Episode 112Chris Arendt, CSO of Takeda, likens the AI overhaul at the pharma to gutting and rebuilding an old house, from the plumbing and electrical up, while you’re still living there. In…
- Ep. 111 - McGill's Angela Genge on why ALS drug development is turning a corner · 37 min · Season 5 Episode 111ALS drug development has long been hampered by heterogeneity, but Angela Genge — neurologist at McGill University and CMO of AL-S Pharma — argues the field is getting closer to…
- Ep. 110 - Richard Pops on Three Decades in Biotech: Drug pricing, FDA and China · 38 min · Season 5 Episode 110Richard Pops has lived the biotech roller coaster over three decades as CEO of Alkermes: an IPO, M&A, near-death events for his company, FDA setbacks, battles with an activist…
- Ep. 109 - Mind the Gap: Karen Knudsen on Fixing Cancer Drug Development · 36 min · Season 5 Episode 109Karen Knudsen, CEO of the Parker Institute for Cancer Immunotherapy, believes the central problem in cancer drug development is not discovery, but a broken “translational…
- Ep. 108 - Rethinking Discovery: Chris Hollowood on Causal Biology and Syncona’s Strategy · 33 min · Season 5 Episode 108A paradigm shift in research tools, combined with large-scale unbiased screening, has positioned the biopharma industry not only to rethink target discovery, but also to execute…
- Ep. 107 - Forbion’s Slootweg on Europe Biotech, NewCos From Asia and Green Investing · 38 min · Season 5 Episode 107The European biotech ecosystem has gone through a substantial maturation process over the past 20 years, as VC funds such as Forbion have experienced exponential growth to fund…
- Ep. 106 - Can the U.K. Capture Biotech Value? Daniel Mahony on Growth, Pricing and Reform · 34 min · Season 5 Episode 106The U.K. is excellent at invention and science, and creating institutions to further innovation, but poor at capturing their economic value, says Daniel Mahony, a problem that…
- Ep. 105 - Recursion’s Najat Khan: AI Will Be Judged by the Medicines It Delivers · 40 min · Season 5 Episode 105As AI spreads across biopharma, what will matter most is not who has the flashiest tools, but who can use them to make better medicines. In this episode of The BioCentury Show…
- Ep. 104 - SoftBank’s Jacqueline Fok on AI Drug Development, Metsera and the U.K. Biotech Opportunity · 35 min · Season 5 Episode 104There is a real opportunity for artificial intelligence to dramatically transform the speed, cost and efficiency of drug development over the long term, but the uptake of AI…
